3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Neoplasms
1
Glioma
1
Glioblastoma
1
Brain Neoplasms
1
Astrocytoma
1
Interventions
Temozolomide
53
Bevacizumab
45
Radiotherapy
28
Radiosurgery
21
Carboplatin
14
Erlotinib Hydrochloride
11
Radiation
10
pembrolizumab
9
Magnetic Resonance Spectroscopy
9
Etoposide
9
Vorinostat
8
Trastuzumab
8
Irinotecan
8
Sunitinib
7
Sorafenib
7
Radiotherapy, Intensity-Modulated
7
Lomustine
7
Lapatinib
7
Capecitabine
7
dabrafenib
6
Ipilimumab
6
Imatinib Mesylate
6
Cyclophosphamide
6
Sirolimus
5
Hydroxyurea
5
Everolimus
5
Bortezomib
5
temsirolimus
4
cabozantinib
4
binimetinib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Brain Neoplasms
×
Trabedersen
×
Clear all
NCT00761280
2014-11-14
SAPPHIRE
Isarna Therapeutics GmbH
Phase 3
Terminated
27 enrolled
28 charts